Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs Tilray Brands Inc (TLRY) Price & Performance

Medpace Holdings IncTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs Tilray Brands Inc — how do they compare? Medpace Holdings Inc trades at $601.68 (market cap $16.90B), while Tilray Brands Inc trades at $4.77 (market cap $649.42M). The key difference: Medpace Holdings Inc is far larger — about 26× Tilray Brands Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.

MEDPTLRY
Market Cap
$16.90B$649.42M
Sector
TechnologyHealth
52-Week High
$620.59$21.00
52-Week Low
$393.42$3.88
Enterprise Value
$16.52B$816.55M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.

Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.

Tilray Brands Inc

TLRY trades at $4.71, up 6.56% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $821M in 2025, yet the company posted a net loss of -$2.19B, reflecting profitability challenges. Recent news highlights growth initiatives, including a partnership with Wolverhampton Wanderers and a new THC pouch launch. The stock remains volatile, with a low P/S of 0.58 and P/B of 0.4, suggesting potential undervaluation amid ongoing losses.

Outlook is cautious; TLRY's path to profitability hinges on revenue growth and cost management. Risks include persistent losses, high debt, and regulatory uncertainty. Analyst consensus is mixed, with 25% buy ratings but 65% hold, indicating skepticism. Investors should weigh growth potential against financial instability and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY